Sugi Predict

Sugi Predict / Targets / MTOR

MTOR

Serine/threonine-protein kinase mTOR · P42345 · MTOR on Sugi Atlas →

413,095 patent compounds predicted against MTOR, 273,235 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12162 SCHEMBL12162 0.74 16/20
SCHEMBL10811 SCHEMBL10811 0.57 16/20
SCHEMBL11807 SCHEMBL11807 0.59 14/20
SCHEMBL9010 SCHEMBL9010 0.54 14/20
SCHEMBL12282 SCHEMBL12282 0.59 13/20
SCHEMBL12315 SCHEMBL12315 0.75 11/20
SCHEMBL12366 SCHEMBL12366 0.67 11/20
SCHEMBL11830 SCHEMBL11830 0.48 11/20
SCHEMBL12351 SCHEMBL12351 0.65 10/20
SCHEMBL10508 SCHEMBL10508 0.61 10/20
SCHEMBL11490 SCHEMBL11490 0.56 10/20
SCHEMBL11313 SCHEMBL11313 0.54 10/20
SCHEMBL12362 SCHEMBL12362 0.54 10/20
SCHEMBL10912 SCHEMBL10912 0.53 9/20
SCHEMBL12192 SCHEMBL12192 0.52 9/20
Temsirolimus Temsirolimus (SCHEMBL18792) 1.00 8/20
SCHEMBL11354 SCHEMBL11354 0.56 8/20
SCHEMBL11284 SCHEMBL11284 0.55 8/20
SCHEMBL11793 SCHEMBL11793 0.51 8/20
SCHEMBL11290 SCHEMBL11290 0.50 8/20

Clinical trials — most relevant to MTOR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Sirolimus Treatment for Refractory PRCA PHASE4COMPLETED
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA PHASE4COMPLETED
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris PHASE4UNKNOWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer PHASE3COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma PHASE1/PHASE2COMPLETED
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients PHASE2UNKNOWN
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer PHASE2COMPLETED
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma PHASE2COMPLETED
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery PHASE2WITHDRAWN
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer PHASE2COMPLETED
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
Temsirolimus as Second-line Therapy in HCC PHASE2UNKNOWN
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas PHASE2COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Everolimus TDM to Predict Long Term Toxicity nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Investigation of an Amino Acid Supplement on Glucose Levels in Obese Subjects nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MTOR binder may also engage these)

ProteinNameSimilarity
Q9JLN9 — 1.000 Q9JLN9 →
P42346 — 1.000 P42346 →
Q5R6J0 — 0.993 Q5R6J0 →
Q6PDI5 — 0.990 Q6PDI5 →
ECPAS Proteasome adapter and scaffold protein ECM29 0.990 landscape →
PDS5A Sister chromatid cohesion protein PDS5 homolog A 0.987 landscape →
A1L1F4 — 0.987 A1L1F4 →
A0A0R4ITC5 — 0.986 A0A0R4ITC5 →
TRRAP Transformation/transcription domain-associated protein 0.986 landscape →
Q6A026 — 0.985 Q6A026 →
Q5F3U9 — 0.985 Q5F3U9 →
A4L9P7 — 0.985 A4L9P7 →
DNAJC13 DnaJ homolog subfamily C member 13 0.985 landscape →
Q5F3V3 — 0.985 Q5F3V3 →
Q5ZL91 — 0.984 Q5ZL91 →
O94915 — 0.984 O94915 →
Q498H0 — 0.983 Q498H0 →
Q9NVH2 — 0.982 Q9NVH2 →
Q7TQK1 — 0.982 Q7TQK1 →
Q4VA53 — 0.982 Q4VA53 →
Q9GM44 — 0.981 Q9GM44 →
Q7TMY8 — 0.981 Q7TMY8 →
Q1RMS6 — 0.981 Q1RMS6 →
Q6TRW4 — 0.981 Q6TRW4 →
A2VE70 — 0.981 A2VE70 →
P21359 — 0.980 P21359 →
B1AY13 — 0.980 B1AY13 →
P97536 — 0.980 P97536 →
CAND1 Cullin-associated NEDD8-dissociated protein 1 0.980 landscape →
Q8IZQ1 — 0.979 Q8IZQ1 →